Suzhou Ribo and Boehringer Ingelheim Achieve New Milestone in siRNA Program for Liver Disease#China#Suzhou#Boehringer_Ingelheim#Ribo_Life_Science#siRNA_Program
Suzhou Ribo and Boehringer Ingelheim Achieve New Milestone in siRNA Program for Liver Disease
Suzhou Ribo Life Science and Boehringer Ingelheim have reached a significant milestone in their collaboration focusing on new therapies for metabolic liver diseases.
third-news.com
May 6, 2026 at 5:12 PM
Suzhou Ribo and Boehringer Ingelheim Achieve New Milestone in siRNA Program for Liver Disease#China#Suzhou#Boehringer_Ingelheim#Ribo_Life_Science#siRNA_Program